LXRX•benzinga•
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
Summary
Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 1, 2024 by benzinga